The luseogliflozin drug market is anticipated to grow at a significant CAGR 4% during the forecast period (2022-2028). Luseogliflozin drug is prescribed in the treatment of type 2 diabetes. The rise in type 2 diabetes-related comorbidities has fueled a more aggressive approach in treatment and the use of multiple-drug therapies. Type 2 diabetes is a chronic condition that distracts the human body from using insulin in a normal manner. Type 2 diabetes is a phase in which the human body becomes insulin resistant. Middle-aged and older age groups people are likely to counter this type of diabetes. In the case of obesity and overweight conditions, this type of diabetes may also affect young teenagers and children. Major symptoms of type 2 diabetes are being thirsty every time, the consistent urge to pee, the vision of the person becoming blurry, unusual weight loss. The pancreas in the body produces a hormone known as insulin. This hormone helps in turning the food that goes into the body into glucose. Individuals affected by diabetes, their body produce insulin but lack the consistent use of the insulin which is needed by the body. The pancreas in the body produces more insulin to make glucose bind with the cells. This process does not work well and glucose enters the blood.
Luseogliflozin drug is an SGLT 2 inhibitor. This drug is a novel scaffold, C-phenyl 1-thio-D-glucitol. Luseogliflozin enhances a process that helps in lowering blood glucose levels. This drug is has been found effective in the excretion of urinary glucose and is stable pharmacokinetics in animals. In the case of cryo-preserved human hepatic clearance, this drug has shown prominent metabolic stability. Luseogliflozin drug is also prescribed with other antihyperglycaemic agents. As per International Diabetes Federation, around 541 million adults globally are at risk of developing type 2 diabetes in 2021. The total count of people with diabetes is going to rise to 643 million by the year 2030. In the year 2021, a total of $966 billion was spent on diabetes in the health sector. In the year 2021, 6.7 million deaths were due to diabetes globally. Around the world, 3 in a total of 4 adults who are affected by diabetes live in middle and low-income nations.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Global Luseogliflozin Drug Market at:
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Disease
o By End-User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Novartis AG, Mitsubishi Tanabe Pharma Corp., Taisho Pharmaceutical Holdings Co., Ltd.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
A full report of Global Luseogliflozin Drug Market is available at:
Luseogliflozin Drug Market Report By Segment
By Disease
• Type 2 diabetes
• Others
By End-User
• Hospital
• Clinic
• Others
About us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company name: Orion Market Reports
Contact person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
